Genocea Biosciences Inc · OTC:GNCAQ
Genocea Biosciences — Investor Presentation (July 2020)
28 slides from Genocea Biosciences's investor presentation, Jul 6, 2020
Slide 1: Better cancer immunotherapies through better antigen selection
Better cancer immunotherapies through better antigen selection July 2020
Slide 2: Disclaimer
This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning our possible or ass
Slide 3: Why Genocea?
Why Genocea? Revolutionary antigen discovery platform TARGETS MATTER PROPRIETARY PLATFORM GEN-009 GEN-011 Two differentiated, clinical stage programs Neoantigen Neoantigen vaccine cell therapy Q2 2020 IND Q3 2020 Significant near-term, Mid-2021 initial clinical data value-creating milestones initial
Slide 4: Why do targets matter?
Why do targets matter? Lesson from infectious Lesson from cancer Optimized disease vaccines immunotherapy neoantigen Wrong antigens → no Responses to certain selection protection, even with neoantigens drives positive critical to strong immune responses checkpoint inhibitor (CPI), TIL therapy outcom
Slide 5: The ATLAS antigen selection difference
The ATLAS™ antigen selection difference output All surface-presented True peptides eliciting anti- antigens tumor T cell responses T cell Peptides recognized by T TCR cells Identifies antigens relevant to patient Peptide Selected Not tumor and immune MHC by 1st-gen Surface-presented necessarily syst
Slide 6: ATLAS: high throughput platform harnessing the immune system for antigen selection
ATLAS: high throughput platform harnessing the immune system for antigen selection Tumor NGS biopsy analysis Unique Bacterial plasmids for vectors Autologous every expressing each dendritic cell Comprehensive candidate candidate neoantigen profiling of patient- and tumor-relevant T cell responses Au
Slide 7: ATLAS identifies tumor-specific, surface-presented neoantigens of CD8+ and CD4+ T cell responses
ATLAS identifies the tumor-specific, surface-presented neoantigens of both CD8+ and CD4+ T cell responses CD8+ T cells CD4+ T cells True neoantigens Irrelevant Concentration Concentration IFNg IFNg InhibigensTM NormalizedBackgroundto Control NormalizedBackgroundto Control Individual mutations Indivi
Slide 8: Inhibigen identification and exclusion is critical to ensure efficacy
Inhibigen identification and exclusion is critical to ensure efficacy 1,600 Adjuvant only 1,000 ) 1,400 Protective vaccine Adjuvant only 3 ) 3 Inhibigens + Adjuvant m 1,200 Protective vaccine + Inhibigen m 800 m ( m ( e 1,000 e m 600 u m l 800 u o l v o r v 600 400 o r m o u 400 m T u 200 T 200 0 0
Slide 9: Antigen selection: Enabling differentiated immune responses
Antigen selection: Enabling differentiated immune responses Including only therapeutically relevant neoantigens Relevant both to tumor and patient immune system (surface-presented and immunogenic) Uniquely identifies Inhibigens for exclusion TARGETS MATTER Comprehensive Any patient, antigen, and can
Slide 10: ATLAS drives emerging immunotherapy pipeline
ATLAS drives emerging immunotherapy pipeline Discovery Pre-IND Phase 1/2a Pivotal Status & Anticipated Milestones GEN-009 – Neoantigen vaccine • ASCO 2019 Top 10 IO abstract • Initial clinical data in Q3 2020 GEN-011 – Neoantigen cell therapy • IND filed in Q2 2020 • Initial clinical data in mid-202
Slide 11: GEN-009 Neoantigen Vaccine
GEN-009 Unprecedented immune responses; Neoantigen Vaccine Emerging clinical efficacy | CONFIDENTIAL 11
Slide 12: Simple, scalable production and delivery
Simple, scalable production and delivery 12
Slide 13: GEN-009 phase 1/2a trial design Part A
GEN-009 phase 1/2a trial design Part A • Vaccine monotherapy in patients with no evidence of disease • Multiple tumor types with CPI approval • Objectives: safety, immunogenicity • Status: all patients in long-term follow-up
Slide 14: Unparalleled immune responses in Part A
Unparalleled immune responses in Part A Frequency Effector Central Memory % neoantigens with Function Response immune responses (ex vivo assay) (IVS assay) CD4+ CD8+ CD4+ CD8+ Best peer results3 60% 99% 51% GEN-0092 87% 41% 57% 57% 23% Best peer results1 GEN-0092 Achieved in combination Monotherapy
Slide 15: No disease progression in almost all Part A patients
No disease progression in almost all Part A patients Patient Tumor Type Recurrence-free Survival of Part A Patients Median follow up of 14 months A NSCLC Compares favorably expected relapse rates in these malignancies B Urothelial C Melanoma Patient H, who has progressed, had low ex vivo immune resp
Slide 16: GEN-009 phase 1/2a trial design Part B
GEN-009 phase 1/2a trial design Part B • Combination of GEN-009 and standard-of-care PD-1-based regimen in patients with advanced disease • Tumor types: Melanoma, NSCLC, SCCHN, Urothelial, RCC • Objectives: safety, immunogenicity, efficacy • Vaccination contribution to be determined after CPI respon
Slide 17: Sample CPI spider plot
Sample CPI spider plot: decreasing change in expected outcome over time Each patient can serve as own control Topalian et al., NEJM 366: 2443-54, 2012 17
Slide 18: GEN-011 Neoantigen T cell Therapy
GEN-011 Potential best-in-class solid tumor Neoantigen T cell Therapy adoptive T cell therapy | CONFIDENTIAL 18
Slide 19: GEN-011 – a new category of neoantigen T cell therapy
GEN-011 – a new category of neoantigen T cell therapy: Peripheral blood-derived, ATLAS™-powered Peripheral blood (leukopak) GEN-011 Up to 30 neoantigens Neoantigen-specific cell expansion in fully closed single-use vessels Autologous, non-engineered 19
Slide 20: GEN-011: Embraces TIL advantages, overcomes limitations
GEN-011: Embraces TIL advantages, overcomes limitations TIL limitations GEN-011 GEN-011 advantages Neoantigen • Targets up to 30 relevant neoantigens with • Limited tumor specificity selection via CD4+ and CD8+ memory T cells • Cannot avoid inhibitory, • Avoids pro-tumor Inhibigens that may pro-tumo
Slide 21: CD4+ and CD8+ memory T cells for anti-tumor efficacy
CD4+ and CD8 + memory T cells for anti-tumor efficacy, persistence and proliferation Pure T cell drug product Desired T cell memory phenotype Non-T cells 100 1% CD8+ y 75 c 35% n e u q 50 e CD4+ r F 65% T cells % 25 99% 0 Naive Terminal Memory memory (Cm+Em) (TEMRA) Data represent mean across cancer
Slide 22: Billions of neoantigen-specific T cells
Billions of neoantigen-specific T cells Contains an average of Majority of T cells are specific for 3.3 billion T cells ATLAS-identified neoantigens 1010 Irrelevant antigens Neoantigens CD8+ 65% r e 5% b + m CD4 u 9 n 10 l l e c T Activation Marker ActivationMarker 2 ActivationMarker 2 108 Pre-expan
Slide 23: GEN-011 T cells are highly functional and cytotoxic
GEN-011 T cells are highly functional and cytotoxic An average of 16,000 cells per T cells are potently million are secreting cytokines in cytolytic against target response to stimulation neoantigens CD8+ 100 Specific Neoantigens + 80 CD4 Unpulsed Control y t i c i 60 Negative x o t control o t y 40
Slide 24: PBL-derived T cells exhibit greater neoantigen activity than TIL
PBL-derived T cells exhibit greater neoantigen activity and potency compared to TIL T cells are activated appropriately Neoantigen-specific T cells upon neoantigen stimulation secrete abundant IFN + 80 CD8 25000 n o i t a l u 20000 g 60 e r p L u r 15000 m / e g k r 40 p a m N 10000 F n I o i t a
Slide 25: Unparalleled breadth of neoantigen coverage
Unparalleled breadth of neoantigen coverage GEN-011 targets up to 30 neoantigens Recent conventional TIL data show responses to an average 89% of 6% of the predicted neoantigens2 Recent selected TIL data show successful amplification to only 4% of antigens included in the process1 GEN-011 T cells ar
Slide 26: Phase 1/2 pilot study of GEN-011 in refractory solid tumors
Trial Objectives Phase 1/2 pilot study of GEN-011 in refractory solid tumors Targeted indications Cohort A Trial objectives Melanoma, NSCLC, SCLC, Multiple low dose • Safety SCCHN, UC, RCC, SqCC skin, (up to 12 patients) • Clinical activity SqCCAC • No lymphodepletion • ORR • Low dose IL-2 Tumors re
Slide 27: Better immunotherapies through better antigen selection
Better immunotherapies through better antigen selection Revolutionary antigen discovery platform TARGETS MATTER PROPRIETARY PLATFORM GEN-009 GEN-011 Two differentiated, clinical stage programs Neoantigen Neoantigen vaccine cell therapy Q2 2020 IND Q3 2020 Significant near-term, Mid-2021 initial clin
Slide 28: Acorn Park Drive Cambridge, MA 02140 USA +1 617.876.8191 www.genocea.com 28
NASDAQ: GNCA 100 Acorn Park Drive Cambridge, MA 02140 USA +1 617.876.8191 www.genocea.com 28
Genocea Biosciences — Investor Presentation (July 2020) on 6ix